On June 26, Abivax S.A. rose 5.48% in regular trading, trading at $96.87/share, with turnover of $50.50 million.

On the news front, the stock saw a notable intraday rebound as the bull-bear debate over safety concerns surrounding its core drug obefazimod intensified. The company's Phase 3 ABTECT maintenance trial previously reported multiple cancer cases in the 50mg dose group, triggering a sharp selloff that took shares from approximately $130 to around $70 — a decline of nearly 50%. However, some investors have since argued that the cancer cases are more likely age-related rather than drug-related, and that the trial successfully met its primary endpoint, suggesting the initial market reaction was excessive.

The stock had previously rebounded above $100 before retreating again in recent sessions amid persistent safety-related uncertainty. The current intraday bounce reflects renewed buying interest as bulls reassert the overreaction thesis, though the broader market consensus on the drug's safety profile remains unresolved.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)